Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
POLLUX Investigators
Research output
:
Contribution to journal
›
Article
›
peer-review
1239
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Daratumumab, lenalidomide, and dexamethasone for multiple myeloma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Myeloma
100%
Lenalidomide
100%
Daratumumab
100%
Confidence Interval
25%
Progression-free Survival
25%
Relapsed or Refractory multiple Myeloma
16%
Neutropenia
16%
Infusion Reaction
16%
Minimal Residual Disease
16%
Kaplan-Meier
8%
Thrombocytopenia
8%
Tumor Cells
8%
Hazard Ratio
8%
Disease Progression
8%
Anemia
8%
Adverse Events
8%
Phase II Trial
8%
Improved Outcomes
8%
Complete Response
8%
Log-rank Test
8%
White Cell
8%
Control Therapy
8%
Interim Analysis
8%
Phase 1/2 Study
8%
Progression Rate
8%
Line of Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Dexamethasone
100%
Multiple Myeloma
100%
Lenalidomide
100%
Daratumumab
100%
Progression Free Survival
25%
Neutropenia
16%
Infusion Related Reaction
16%
Minimal Residual Disease
16%
Neoplasm
8%
Adverse Event
8%
Anemia
8%
Thrombocytopenia
8%
Disease Exacerbation
8%
Immunology and Microbiology
Dexamethasone
100%
Multiple Myeloma
100%
Lenalidomide
100%
Daratumumab
100%
Progression Free Survival
25%
Tumor Cell
8%
Leukocyte
8%
Biochemistry, Genetics and Molecular Biology
Dexamethasone
100%
Progression Free Survival
75%
Leukocyte
25%
Thrombocytopenia
25%